UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2017
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 001-35299
ALKERMES PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
Ireland |
|
98-1007018 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
Connaught House
1 Burlington Road
Dublin 4, Ireland
(Address of principal executive offices)
+ 353-1-772-8000
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files): Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☒ |
|
Accelerated filer ☐ |
|
|
|
Non-accelerated filer ☐ |
|
Smaller reporting company ☐ |
(Do not check if a smaller reporting company) |
|
Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒
The number of the registrant’s ordinary shares, $0.01 par value, outstanding as of October 23, 2017 was 153,775,930 shares.
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2017
|
|
|
|
Page No. |
|
|
||
|
||
|
Condensed Consolidated Balance Sheets — September 30, 2017 and December 31, 2016 |
5 |
|
6 | |
|
7 | |
|
8 | |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
22 | |
35 | ||
36 | ||
|
|
|
|
||
36 | ||
36 | ||
37 | ||
38 | ||
39 |
2
Cautionary Note Concerning Forward-Looking Statements
This document contains and incorporates by reference “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, these statements can be identified by the use of forward-looking terminology such as “may,” “will,” “could,” “should,” “would,” “expect,” “anticipate,” “continue,” “believe,” “plan,” “estimate,” “intend” or other similar words. These statements discuss future expectations, and contain projections of results of operations or of financial condition, or state trends and known uncertainties or other forward-looking information. Forward-looking statements in this Quarterly Report on Form 10-Q (“Form 10-Q”) include, without limitation, statements regarding:
• our expectations regarding our financial performance, including revenues, expenses, gross margins, liquidity, capital expenditures and income taxes;
• our expectations regarding our products, including the development, regulatory (including expectations about regulatory filings, regulatory approvals and regulatory timelines), therapeutic and commercial scope and potential of such products and the costs and expenses related thereto;
• our expectations regarding the initiation, timing and results of clinical trials of our products;
• our expectations regarding the competitive landscape, and changes therein, related to our products, including competition from generic forms of our products, our development programs, and our industry generally;
• our expectations regarding the financial impact of currency exchange rate fluctuations and valuations;
• our expectations regarding future amortization of intangible assets;
• our expectations regarding our collaborations, licensing arrangements and other significant agreements with third parties relating to our products, including our development programs;
• our expectations regarding the impact of adoption of new accounting pronouncements;
• our expectations regarding near‑term changes in the nature of our market risk exposures or in management’s objectives and strategies with respect to managing such exposures;
• our ability to comply with restrictive covenants of our indebtedness and our ability to fund our debt service obligations;
• our expectations regarding future capital requirements and capital expenditures and our ability to finance our operations and capital requirements;
• our expectations regarding the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents, other proprietary and intellectual property rights, and our products, including the commercialization of such products; and
• other factors discussed elsewhere in this Form 10-Q.
Actual results might differ materially from those expressed or implied by these forward‑looking statements because these forward‑looking statements are subject to risks, assumptions and uncertainties. You are cautioned not to place undue reliance on these forward‑looking statements, which speak only as of the date of this Form 10-Q. All subsequent written and oral forward‑looking statements concerning the matters addressed in this Form 10-Q and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Except as required by applicable law or regulation, we do not undertake any obligation to publicly update or revise any forward‑looking statements, whether as a result of new information, future events or otherwise. In light of these risks, assumptions and uncertainties, the forward‑looking events discussed in this Form 10-Q might not occur. For more information regarding the risks and uncertainties of our business, see “Part II, Item 1A – Risk Factors” in this Form 10-Q and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 and “Part I, Item 1A—Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2016 (the “Annual Report”) and any subsequent reports filed with the United States (“U.S.”) Securities and Exchange Commission (“SEC”).
Unless otherwise indicated, information contained in this Form 10-Q concerning the disorders targeted by our products and the markets in which we operate is based on information from various sources (including, without limitation, industry publications, medical and clinical journals; studies; surveys and forecasts; and our internal research), on assumptions that we have made, which we believe are reasonable, based on such information, and on our knowledge of the markets for our products. Our internal research has not been verified by any independent source, and we have not independently verified any third‑party information. Such information and assumptions are necessarily subject to a high
3
degree of uncertainty and risk due to a variety of factors, including those described in “Part II, Item 1A – Risk Factors” in this Form 10-Q and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 and “Part I, Item 1A—Risk Factors” of our Annual Report. These and other factors could cause our results to differ materially from those expressed in this Form 10-Q.
Note Regarding Company and Product References
Alkermes plc (as used in this report, together with our subsidiaries, “Alkermes,” the “Company,” “us,” “we” and “our”) is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. We have a diversified portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (“CNS”) disorders such as schizophrenia, depression, addiction and multiple sclerosis (“MS”). Except as otherwise suggested by the context, (a) references to “products” or “our products” in this Form 10-Q include our marketed products, marketed products using our proprietary technologies, our product candidates, product candidates using our proprietary technologies, development products and development products using our proprietary technologies, (b) references to the “biopharmaceutical industry” are used interchangeably with references to the “biotechnology” and/or “pharmaceutical industries” and (c) references to “licensees” are used interchangeably with references to “collaborative partners” and “partners.”
Note Regarding Trademarks
We are the owner of various U.S. federal trademark registrations (“®”) and other trademarks (“TM”), including ARISTADA®, LinkeRx®, NanoCrystal® and VIVITROL®.
The following are trademarks of the respective companies listed: AMPYRA® and FAMPYRA®—Acorda Therapeutics, Inc. (“Acorda”); BYDUREON® —Amylin Pharmaceuticals, LLC; INVEGA SUSTENNA®, INVEGA TRINZA®, TREVICTA®, XEPLION®, and RISPERDAL CONSTA®—Johnson & Johnson (or its affiliates); TECFIDERA®—Biogen MA Inc. (“Biogen”); and ZYPREXA®—Eli Lilly and Company. Other trademarks, trade names and service marks appearing in this Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Form 10-Q are referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.
4
Item 1. Condensed Consolidated Financial Statements:
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
|
|
September 30, 2017 |
|
December 31, 2016 |
||
|
|
(In thousands, except share and per share amounts) |
||||
ASSETS |
|
|
|
|
|
|
CURRENT ASSETS: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
165,123 |
|
$ |
186,378 |
Investments—short-term |
|
|
284,977 |
|
|
310,856 |
Receivables, net |
|
|
207,537 |
|
|
191,102 |
Inventory |
|
|
85,027 |
|
|
62,998 |
Prepaid expenses and other current assets |
|
|
38,887 |
|
|
39,344 |
Total current assets |
|
|
781,551 |
|
|
790,678 |
INTANGIBLE ASSETS—NET |
|
|
271,811 |
|
|
318,227 |
PROPERTY, PLANT AND EQUIPMENT, NET |
|
|
270,666 |
|
|
264,785 |
INVESTMENTS—LONG-TERM |
|
|
118,751 |
|
|
121,931 |
GOODWILL |
|
|
92,873 |
|
|
92,873 |
CONTINGENT CONSIDERATION |
|
|
79,100 |
|
|
63,200 |
DEFERRED TAX ASSETS |
|
|
117,453 |
|
|
47,768 |
OTHER ASSETS |
|
|
16,121 |
|
|
26,961 |
TOTAL ASSETS |
|
$ |
1,748,326 |
|
$ |
1,726,423 |
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
CURRENT LIABILITIES: |
|
|
|
|
|
|
Accounts payable and accrued expenses |
|
$ |
251,187 |
|
$ |
207,055 |
Long-term debt—short-term |
|
|
3,000 |
|
|
3,000 |
Deferred revenue—short-term |
|
|
1,827 |
|
|
1,938 |
Total current liabilities |
|
|
256,014 |
|
|
211,993 |
LONG-TERM DEBT |
|
|
278,994 |
|
|
280,666 |
OTHER LONG-TERM LIABILITIES |
|
|
19,906 |
|
|
17,161 |
DEFERRED REVENUE—LONG-TERM |
|
|
6,132 |
|
|
7,122 |
Total liabilities |
|
|
561,046 |
|
|
516,942 |
COMMITMENTS AND CONTINGENCIES (Note 12) |
|
|
|
|
|
|
SHAREHOLDERS’ EQUITY: |
|
|
|
|
|
|
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at September 30, 2017 and December 31, 2016, respectively |
|
|
— |
|
|
— |
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 155,793,163 and 154,191,281 shares issued; 153,745,656 and 152,430,514 shares outstanding at September 30, 2017, and December 31, 2016, respectively |
|
|
1,555 |
|
|
1,539 |
Treasury shares, at cost (2,047,507 and 1,760,767 shares at September 30, 2017 and December 31, 2016, respectively) |
|
|
(89,311) |
|
|
(72,639) |
Additional paid-in capital |
|
|
2,312,865 |
|
|
2,231,797 |
Accumulated other comprehensive loss |
|
|
(3,253) |
|
|
(3,274) |
Accumulated deficit |
|
|
(1,034,576) |
|
|
(947,942) |
Total shareholders’ equity |
|
|
1,187,280 |
|
|
1,209,481 |
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
$ |
1,748,326 |
|
$ |
1,726,423 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
September 30, |
|
September 30, |
||||||||
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
||||
|
|
(In thousands, except per share amounts) |
||||||||||
REVENUES: |
|
|
|
|
|
|
|
|
|
|
|
|
Manufacturing and royalty revenues |
|
$ |
122,677 |
|
$ |
110,250 |
|
$ |
366,608 |
|
$ |
353,444 |
Product sales, net |
|
|
93,681 |
|
|
69,802 |
|
|
258,893 |
|
|
176,695 |
Research and development revenue |
|
|
1,027 |
|
|
189 |
|
|
2,503 |
|
|
2,042 |
Total revenues |
|
|
217,385 |
|
|
180,241 |
|
|
628,004 |
|
|
532,181 |
EXPENSES: |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below) |
|
|
36,054 |
|
|
35,456 |
|
|
116,241 |
|
|
97,165 |
Research and development |
|
|
104,411 |
|
|
99,444 |
|
|
308,399 |
|
|
297,523 |
Selling, general and administrative |
|
|
99,633 |
|
|
91,145 |
|
|
310,682 |
|
|
276,985 |
Amortization of acquired intangible assets |
|
|
15,643 |
|
|
15,323 |
|
|
46,417 |
|
|
45,636 |
Total expenses |
|
|
255,741 |
|
|
241,368 |
|
|
781,739 |
|
|
717,309 |
OPERATING LOSS |
|
|
(38,356) |
|
|
(61,127) |
|
|
(153,735) |
|
|
(185,128) |
OTHER (EXPENSE) INCOME, NET: |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
1,173 |
|
|
912 |
|
|
3,287 |
|
|
2,917 |
Interest expense |
|
|
(3,129) |
|
|
(3,375) |
|
|
(8,816) |
|
|
(9,993) |
Change in the fair value of contingent consideration |
|
|
13,600 |
|
|
(1,000) |
|
|
15,900 |
|
|
3,100 |
Other expense, net |
|
|
(9,078) |
|
|
(752) |
|
|
(10,696) |
|
|
(970) |
Total other (expense) income, net |
|
|
2,566 |
|
|
(4,215) |
|
|
(325) |
|
|
(4,946) |
LOSS BEFORE INCOME TAXES |
|
|
(35,790) |
|
|
(65,342) |
|
|
(154,060) |
|
|
(190,074) |
INCOME TAX (BENEFIT) PROVISION |
|
|
486 |
|
|
(2,655) |
|
|
(5,904) |
|
|
(2,771) |
NET LOSS |
|
$ |
(36,276) |
|
$ |
(62,687) |
|
$ |
(148,156) |
|
$ |
(187,303) |
LOSS PER COMMON SHARE: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
(0.24) |
|
$ |
(0.41) |
|
$ |
(0.97) |
|
$ |
(1.24) |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
153,684 |
|
|
151,652 |
|
|
153,263 |
|
|
151,261 |
COMPREHENSIVE LOSS: |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(36,276) |
|
$ |
(62,687) |
|
$ |
(148,156) |
|
$ |
(187,303) |
Holding gain (loss), net of a tax (benefit) provision of $35, $(129), $(14) and $445, respectively |
|
|
83 |
|
|
(261) |
|
|
22 |
|
|
988 |
COMPREHENSIVE LOSS |
|
$ |
(36,193) |
|
$ |
(62,948) |
|
$ |
(148,134) |
|
$ |
(186,315) |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
|
|
Nine Months Ended |
||||
|
|
September 30, |
||||
|
|
2017 |
|
2016 |
||
|
|
(In thousands) |
||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
|
Net loss |
|
$ |
(148,156) |
|
$ |
(187,303) |
Adjustments to reconcile net loss to cash flows from operating activities: |
|
|
|
|
|
|
Depreciation and amortization |
|
|
73,305 |
|
|
69,605 |
Share-based compensation expense |
|
|
63,336 |
|
|
74,613 |
Impairment of investment in Reset Therapeutics, Inc. |
|
|
10,471 |
|
|
— |
Deferred income taxes |
|
|
(11,919) |
|
|
(12,545) |
Excess tax benefit from share-based compensation |
|
|
— |
|
|
(5,118) |
Change in the fair value of contingent consideration |
|
|
(15,900) |
|
|
(3,100) |
Other non-cash charges |
|
|
3,357 |
|
|
1,901 |
Changes in assets and liabilities: |
|
|
|
|
|
|
Receivables |
|
|
(16,434) |
|
|
(21,960) |
Inventory |
|
|
(21,843) |
|
|
(17,156) |
Prepaid expenses and other assets |
|
|
(1,944) |
|
|
(1,110) |
Accounts payable and accrued expenses |
|
|
43,430 |
|
|
26,833 |
Deferred revenue |
|
|
(1,102) |
|
|
(526) |
Other long-term liabilities |
|
|
6,680 |
|
|
4,506 |
Cash flows used in operating activities |
|
|
(16,719) |
|
|
(71,360) |
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
|
|
Additions of property, plant and equipment |
|
|
(33,482) |
|
|
(33,787) |
Proceeds from the sale of equipment |
|
|
50 |
|
|
100 |
Investment in Reset Therapeutics, Inc. |
|
|
— |
|
|
(15,000) |
Purchases of investments |
|
|
(289,226) |
|
|
(296,712) |
Sales and maturities of investments |
|
|
318,492 |
|
|
493,520 |
Cash flows (used in) provided by investing activities |
|
|
(4,166) |
|
|
148,121 |
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
|
|
Proceeds from the issuance of ordinary shares under share-based compensation arrangements |
|
|
18,298 |
|
|
12,746 |
Excess tax benefit from share-based compensation |
|
|
— |
|
|
5,118 |
Employee taxes paid related to net share settlement of equity awards |
|
|
(16,418) |
|
|
(8,432) |
Principal payments of long-term debt |
|
|
(2,250) |
|
|
(65,063) |
Cash flows used in financing activities |
|
|
(370) |
|
|
(55,631) |
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS |
|
|
(21,255) |
|
|
21,130 |
CASH AND CASH EQUIVALENTS—Beginning of period |
|
|
186,378 |
|
|
181,109 |
CASH AND CASH EQUIVALENTS—End of period |
|
$ |
165,123 |
|
$ |
202,239 |
SUPPLEMENTAL CASH FLOW DISCLOSURE: |
|
|
|
|
|
|
Non-cash investing and financing activities: |
|
|
|
|
|
|
Purchased capital expenditures included in accounts payable and accrued expenses |
|
$ |
5,321 |
|
$ |
3,642 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7
ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Unaudited)
Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of marketed drug products and a clinical pipeline of products that address CNS disorders such as schizophrenia, depression, addiction and MS. Headquartered in Dublin, Ireland, Alkermes has a research and development (“R&D”) center in Waltham, Massachusetts; an R&D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying condensed consolidated financial statements of the Company for the three and nine months ended September 30, 2017 and 2016 are unaudited and have been prepared on a basis substantially consistent with the audited financial statements for the year ended December 31, 2016. The year-end condensed consolidated balance sheet data, which is presented for comparative purposes, was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S. (commonly referred to as “GAAP”). In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, that are necessary to state fairly the results of operations for the reported periods.
These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto of the Company, which are contained in the Company’s Annual Report that has been filed with the SEC. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year.
Principles of Consolidation
The condensed consolidated financial statements include the accounts of Alkermes plc and its wholly-owned subsidiaries as disclosed in Note 2, Summary of Significant Accounting Policies, in the “Notes to Consolidated Financial Statements” accompanying its Annual Report. Intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, judgments, assumptions and methodologies, including those related to revenue recognition and related allowances, its collaborative relationships, clinical trial expenses, the valuation of inventory, impairment and amortization of intangibles and long-lived assets, share-based compensation expense, income taxes including the valuation allowance for deferred tax assets, valuation of contingent consideration, valuation of investments and litigation loss contingencies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.
Segment Information
The Company operates as one business segment, which is the business of developing, manufacturing and commercializing medicines. The Company’s chief decision maker, the Chairman of the Board and Chief Executive Officer, reviews the Company’s operating results on an aggregate basis and manages the Company’s operations as a single operating unit.
8
ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Unaudited) (Continued)
Income Taxes
The Company’s income tax (benefit) provision in the three and nine months ended September 30, 2017 and 2016 primarily relates to U.S. federal and state taxes. The Company records a deferred tax asset or liability based on the difference between the financial statement and tax basis of its assets and liabilities, as measured by enacted jurisdictional tax rates assumed to be in effect when these differences reverse. At September 30, 2017, the Company maintained a valuation allowance against certain of its U.S. and foreign deferred tax assets. The Company evaluates, at each reporting period, the need for a valuation allowance on its deferred tax assets on a jurisdiction-by-jurisdiction basis.
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued guidance that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.
In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Numerous updates have been issued subsequent to the initial guidance that provide clarification on a number of specific issues and require additional disclosures.
This guidance becomes effective for the Company in its year ending December 31, 2018 and the Company will adopt it using the modified retrospective method. The Company has determined that the new guidance will necessitate a change in how it records manufacturing revenue for certain of its arrangements with its collaborative partners. Under current GAAP, the Company records manufacturing revenue from the sale of products it manufactures for resale by its collaborative partners after the Company has shipped such products and risk of loss has passed to the Company’s collaborative partner, assuming persuasive evidence of an arrangement exists, the sales price is fixed or determinable and collectability is reasonably assured. Under the new guidance, the terms within certain of the Company’s manufacturing contracts will require that manufacturing revenue be recorded as products are manufactured rather than upon shipment. Revenue earned under the Company’s other manufacturing contracts will continue to be recorded upon shipment. The Company continues to assess the impact this new guidance will have on its consolidated financial statements, and to evaluate the disclosure requirements under this new guidance.
In January 2016, the FASB issued guidance that enhances the reporting model for financial instruments by addressing certain aspects of recognition, measurement, presentation and disclosure of financial instruments. The amendments in this guidance include: requiring equity securities to be measured at fair value with changes in fair value recognized through the income statement; simplifying the impairment assessment of equity instruments without readily determinable fair values by requiring a qualitative assessment to identify impairment; eliminating the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities; eliminating the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requiring public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requiring an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requiring separate presentation of financial assets and financial liabilities by measurement category and form of financial asset; and clarifying that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to
9
ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Unaudited) (Continued)
available-for-sale securities in combination with the entity’s other deferred tax assets. This guidance becomes effective for the Company in its year ending December 31, 2018, and the Company is in the process of assessing the impact that this guidance will have on its consolidated financial statements.
In February 2016, the FASB issued guidance to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The main difference between previous GAAP and this guidance is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. This guidance becomes effective for the Company in its year ending December 31, 2019, and the Company is currently assessing the impact that this guidance will have on its consolidated financial statements.
In March 2016, the FASB issued guidance as part of its simplification initiative to eliminate the requirement to retroactively adopt the equity method of accounting when an investment qualifies for the use of the equity method as a result of an increase in the level of ownership interest or degree of influence. This guidance became effective for the Company on January 1, 2017, and the adoption of this guidance did not have an impact on its consolidated financial statements.
In March 2016, the FASB issued guidance as part of its simplification initiative that involves several aspects of the accounting for share-based payment transactions. The amendments in this update established that: (i) all excess tax benefits and tax deficiencies be recognized as income tax expense or benefit in the income statement; (ii) excess tax benefits be classified as an operating activity in the statement of cash flows; (iii) the entity make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest, which is current GAAP, or account for forfeitures as they occur; (iv) the threshold to qualify for equity classification permits withholding up to the maximum statutory tax rates in the applicable jurisdictions; and (v) cash paid by an employer when directly withholding shares for tax withholding purposes be classified as a financing activity in the statement of cash flows. This guidance became effective for the Company on January 1, 2017. The amendments related to (i), (iii) and (iv) were adopted by the Company on a modified retrospective basis, which resulted in a cumulative-effect adjustment to reduce accumulated deficit by $61.5 million related to the timing of when excess tax benefits are recognized. The Company elected to continue to record expense only for those awards that are expected to vest. The amendments related to (ii) and (v) were adopted using the prospective transition method.
In June 2016, the FASB issued guidance to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. To achieve this objective, the amendments in this guidance replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance becomes effective for the Company in its year ending December 31, 2020, with early adoption permitted for the Company in its year ending December 31, 2019. The Company is currently assessing the impact that this guidance will have on its consolidated financial statements.
In August 2016, the FASB issued guidance to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This guidance becomes effective for the Company in its year ending December 31, 2018, with early adoption permitted. The Company elected to early adopt this guidance as of January 1, 2017. The adoption of this guidance had no impact on the Company’s statement of cash flows.
In October 2016, the FASB issued guidance to simplify and improve accounting on transfers of assets between affiliated entities. The updated guidance eliminates the prohibition for all intra-entity asset transfers, except for inventory. This guidance becomes effective for the Company in its year ending December 31, 2018, and the Company is currently assessing the impact this guidance will have on its consolidated financial statements.
In January 2017, the FASB issued guidance to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of
10
ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Unaudited) (Continued)
assets or businesses. This guidance becomes effective for the Company in its year ending December 31, 2018, with early adoption permitted for transactions that occurred before the issuance date or effective date of the guidance if the transactions were not reported in financial statements that have been issued or made available for issuance. The Company elected to early adopt this guidance, as of January 1, 2017. The adoption of this guidance had no impact on the Company’s consolidated financial statements.
In January 2017, the FASB issued guidance that simplifies the test for goodwill impairment. This guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. Under the amended guidance, a goodwill impairment charge will now be recognized for the amount by which the carrying value of a reporting unit exceeds its fair value, not to exceed the carrying amount of goodwill. This guidance is effective for the Company in its year ending December 31, 2020, with early adoption permitted for any impairment tests performed after January 1, 2017. The Company elected to early adopt this guidance as of January 1, 2017. The adoption of this guidance had no impact on the Company’s consolidated financial statements.
In May 2017, the FASB issued guidance that amends the scope of modification accounting for share-based payment arrangements that addresses both diversity in practice and the cost and complexity of accounting for the change to the terms or conditions of a share-based payment award. The amendment provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The guidance becomes effective for the Company in its year ending December 31, 2018 and early adoption is permitted. The Company has determined that the adoption of this guidance will not have an impact on its consolidated financial statements unless certain of its share-based payment awards are modified in the future.
In July 2017, the FASB issued guidance that addresses narrow issues identified as a result of the complexity associated with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The guidance becomes effective for the Company in its year ending December 31, 2019 and early adoption is permitted. The Company is currently assessing the impact that this guidance will have on its consolidated financial statements.
11
ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Unaudited) (Continued)
3. INVESTMENTS
Investments consisted of the following (in thousands):
|
|
Amortized |
|
Gross Unrealized |
|
Estimated |
||||||
September 30, 2017 |
|
Cost |
|
Gains |
|
Losses(1) |
|
Fair Value |
||||
Short-term investments: |
|
|
|
|
|
|
|
|
|
|
|
|
Available-for-sale securities: |
|
|
|
|
|
|
|
|
|
|
|
|
U.S. government and agency debt securities |
|
$ |
185,965 |
|
$ |
4 |
|
$ |
(191) |
|
$ |
185,778 |
Corporate debt securities |
|
|
71,722 |
|
|
38 |
|
|
(29) |
|
|
71,731 |
International government agency debt securities |
|
|
27,501 |
|
|
1 |
|
|
(34) |
|
|
27,468 |
Total short-term investments |
|
|
285,188 |
|
|
43 |
|
|
(254) |
|
|
284,977 |
Long-term investments: |
|
|
|
|
|
|
|
|
|
|
|
|
Available-for-sale securities: |
|
|
|
|
|
|
|
|
|
|
|
|
U.S. government and agency debt securities |
|
|
50,561 |
|
|
— |
|
|
(170) |
|
|
50,391 |
Corporate debt securities |
|
|
46,949 |
|
|
— |
|
|
(62) |
|
|
46,887 |
International government agency debt securities |
|
|
17,910 |
|
|
— |
|
|
(25) |
|
|
17,885 |
|
|
|
115,420 |
|
|
— |
|
|
(257) |
|
|
115,163 |
Held-to-maturity securities: |
|
|
|
|
|
|
|
|
|
|
|
|
Fixed term deposit account |
|
|
1,667 |
|
|
192 |
|
|
— |
|
|
1,859 |
Certificates of deposit |
|
|
1,729 |
|
|
— |
|
|
— |
|
|
1,729 |
|
|
|
3,396 |
|
|
192 |
|
|
— |
|
|
3,588 |
Total long-term investments |
|
|
118,816 |
|
|
192 |
|
|
(257) |
|
|
118,751 |
Total investments |
|
$ |
404,004 |
|
$ |
235 |
|
$ |
(511) |
|
$ |
403,728 |
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
Short-term investments: |
|
|
|
|
|
|
|
|
|
|
|
|
Available-for-sale securities: |
|
|
|
|
|
|
|
|
|
|
|
|
U.S. government and agency debt securities |
|
$ |
177,203 |
|
$ |
96 |
|
$ |
(51) |
|
$ |
177,248 |
Corporate debt securities |
|
|
128,119 |
|
|
47 |
|
|
(53) |
|
|
128,113 |
International government agency debt securities |
|
|
5,511 |
|
|
— |
|
|
(16) |
|
|
5,495 |
Total short-term investments |
|
|
310,833 |
|
|
143 |
|
|
(120) |
|
|
310,856 |
Long-term investments: |
|
|
|
|
|
|
|
|
|
|
|
|
Available-for-sale securities: |
|
|
|
|
|
|
|
|
|
|
|
|
U.S. government and agency debt securities |
|
|
81,839 |
|
|
— |
|
|
(391) |
|
|
81,448 |
Corporate debt securities |
|
|
31,223 |
|
|
— |
|
|
(89) |
|
|
31,134 |
International government agency debt securities |
|
|
5,992 |
|
|
— |
|
|
(18) |
|
|
5,974 |
|
|
|
119,054 |
|
|
— |
|
|
(498) |
|
|
118,556 |
Held-to-maturity securities: |
|
|
|
|
|
|
|
|
|
|
|
|
Fixed term deposit account |
|
|
1,667 |
|
|
— |
|
|
(7) |
|
|
1,660 |
Certificates of deposit |
|
|
1,715 |
|
|
— |
|
|
— |
|
|
1,715 |
|
|
|
3,382 |
|
|
— |
|
|
(7) |
|
|
3,375 |
Total long-term investments |
|
|
122,436 |
|
|
— |
|
|
(505) |
|
|
121,931 |
Total investments |
|
$ |
433,269 |
|
$ |
143 |
|
$ |
(625) |
|
$ |
432,787 |
(1) |
Losses represent marketable securities that were in loss positions for less than one year. |
The proceeds from the sales and maturities of marketable securities, which were primarily reinvested and resulted in realized gains and losses, were as follows:
|
|
Nine Months Ended |
||||
|
|
September 30, |
||||
(In thousands) |
|
2017 |
|
2016 |
||
Proceeds from the sales and maturities of marketable securities |
|
$ |
318,492 |
|
$ |
493,520 |
Realized gains |
|
$ |
9 |
|
$ |
124 |
Realized losses |
|
$ |
3 |
|
$ |
28 |
12
ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Unaudited) (Continued)
The Company’s available-for-sale and held-to-maturity securities at September 30, 2017 had contractual maturities in the following periods:
|
|
Available-for-sale |
|
Held-to-maturity |
||||||||
|
|
Amortized |
|
Estimated |
|
Amortized |
|
Estimated |
||||
(In thousands) |
|
Cost |
|
Fair Value |
|
Cost |
|
Fair Value |
||||
Within 1 year |
|
$ |
251,360 |
|
$ |
251,134 |
|
$ |
1,729 |
|
$ |
1,729 |
After 1 year through 5 years |
|
|
149,248 |
|
|
149,006 |
|
|
1,667 |
|
|
1,859 |
Total |
|
$ |
400,608 |
|
$ |
400,140 |
|
$ |
3,396 |
|
$ |
3,588 |
At September 30, 2017, the Company believed that the unrealized losses on its available-for-sale investments were temporary. The investments with unrealized losses consisted primarily of U.S. government and agency debt securities. In making the determination that the decline in fair value of these securities was temporary, the Company considered various factors, including, but not limited to: the length of time each security was in an unrealized loss position; the extent to which fair value was less than cost; financial condition and near-term prospects of the issuers; the Company’s intent not to sell these securities; and the assessment that it is more likely than not that the Company would not be required to sell these securities before the recovery of their amortized cost basis.
In February 2016, the Company entered into a collaboration and license option agreement with Reset Therapeutics, Inc. (“Reset”), a related party. The Company made an upfront, non-refundable payment of $10.0 million in partial consideration of the grant to the Company of the rights and licenses included in such agreement, which was included in R&D expense in the three months ended March 31, 2016, and simultaneously made a $15.0 million investment in exchange for shares of Reset’s Series B Preferred Stock. The Company is accounting for its investment in Reset under the equity method based on its percentage of ownership of Reset, its seat on Reset’s board of directors and its belief that it can exert significant influence over the operating and financial policies of Reset. During the three months ended September 30, 2017, the Company recorded an other-than-temporary impairment charge of $10.5 million, which represented the Company’s remaining investment in Reset, as the Company believes that Reset is unable to generate future earnings that justify the carrying amount of the investment. The impairment charge was recorded within “Other (expense) income, net” in the accompanying condensed consolidated statements of operations and comprehensive loss.
In May 2014, the Company entered into an agreement whereby it is committed to provide up to €7.4 million to a partnership, Fountain Healthcare Partners II, L.P. of Ireland (“Fountain”), which was created to carry on the business of investing exclusively in companies and businesses engaged in the healthcare, pharmaceutical and life sciences sectors. As of September 30, 2017, the Company’s total contribution in Fountain was equal to €3.3 million. The Company’s commitment represents approximately 7% of the partnership’s total funding, and the Company is accounting for its investment in Fountain under the equity method. During the three and nine months ended September 30, 2017, the Company recorded an increase in its investment in Fountain of less than $0.1 million and a decrease in its investment in Fountain of $0.6 million, respectively, which represents the Company’s proportional share of Fountain’s net gains (losses) for these periods. The Company’s $2.7 million net investment in Fountain at September 30, 2017 is included within “Other assets” in the accompanying condensed consolidated balance sheets.
13
ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Unaudited) (Continued)
4. FAIR VALUE MEASUREMENTS
The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:
|
|
September 30, |
|
|
|
|
|
|
|
|
|
|
(In thousands) |
|
2017 |
|
Level 1 |
|
Level 2 |
|
Level 3 |
||||
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents |
|
$ |
1,859 |
|
$ |
1,859 |
|
$ |
— |
|
$ |
— |
U.S. government and agency debt securities |
|
|
236,169 |
|
|
146,717 |
|
|
89,452 |
|
|
— |
Corporate debt securities |
|
|
118,618 |
|
|
— |
|
|
118,618 |
|
|
— |
International government agency debt securities |
|
|
45,353 |
|
|
— |
|
|
45,353 |
|
|
— |
Contingent consideration |
|
|
79,100 |
|
|
— |
|
|
— |
|
|
79,100 |
Common stock warrants |
|
|
1,459 |
|
|
— |
|
|
— |
|
|
1,459 |
Total |
|
$ |
482,558 |
|
$ |
148,576 |
|
$ |
253,423 |
|
$ |
80,559 |
|
|
December 31, |
|
|
|
|
|
|
|
|
|
|
|
|
2016 |
|
Level 1 |
|
Level 2 |
|
Level 3 |
||||
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents |
|
$ |
1,660 |
|
$ |
1,660 |
|
$ |
— |
|
$ |
— |
U.S. government and agency debt securities |
|
|
258,696 |
|
|
156,370 |
|
|
102,326 |
|
|
— |
Corporate debt securities |
|
|
159,247 |
|
|
— |
|
|
159,247 |
|
|
— |
International government agency debt securities |
|
|
11,469 |
|
|
— |
|
|
11,469 |
|
|
— |
Contingent consideration |
|
|
63,200 |
|
|
— |
|
|
— |
|
|
63,200 |
Common stock warrants |
|
|
1,392 |
|
|
— |
|
|
— |
|
|
1,392 |
Total |
|
$ |
495,664 |
|
$ |
158,030 |
|
$ |
273,042 |
|
$ |
64,592 |
The Company transfers its financial assets and liabilities, measured at fair value on a recurring basis, between the fair value hierarchies at the end of each reporting period. There were no transfers of any securities between the fair value hierarchies during the nine months ended September 30, 2017.
The Company’s investments in U.S. government and agency debt securities, corporate debt securities and international government agency debt securities classified as Level 2 within the fair value hierarchy were initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing market-observable data. The market-observable data included reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validated the prices developed using the market-observable data by obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active.
The following table is a rollforward of the fair value of the Company’s assets whose fair values were determined using Level 3 inputs at September 30, 2017:
(In thousands) |
|
Fair Value |
|
Balance, January 1, 2017 |
|
$ |
64,592 |
Increase in the fair value of contingent consideration |
|
|
15,900 |
Increase in the fair value of warrants |
|
|
67 |
Balance, September 30, 2017 |
|
$ |
80,559 |
In March 2015, the Company entered into a definitive agreement to sell its Gainesville, GA facility, the related manufacturing and royalty revenue associated with certain products manufactured at the facility, and the rights to IV/IM and other parenteral forms of Meloxicam and certain intellectual property related to IV/IM and parenteral forms of Meloxicam (the “Gainesville Transaction”) to Recro Pharma, Inc. (“Recro”) and Recro Pharma LLC. In connection with the Gainesville Transaction, the Company is eligible to receive low double-digit royalties on net sales of IV/IM and parenteral forms of Meloxicam and any other product with the same active ingredient as Meloxicam IV/IM that is discovered or identified using certain of the Company’s intellectual property to which Recro was provided a right of use,
14
ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Unaudited) (Continued)
through license or transfer, pursuant to the Gainesville Transaction (together, the “Meloxicam Product(s)”) and up to $125.0 million in milestone payments upon the achievement of certain regulatory and sales milestones related to the Meloxicam Products, including, at Recro’s election, either (i) $10.0 million upon the submission of a New Drug Application (“NDA”) filing for the first Meloxicam Product and $30.0 million upon regulatory approval of a NDA for the first Meloxicam Product or (ii) an aggregate of $45.0 million upon regulatory approval of a NDA for the first Meloxicam Product. In July 2017, Recro submitted a NDA to the FDA for a Meloxicam Product and elected to pay the Company under scenario (ii) an aggregate of $45.0 million upon regulatory approval of the NDA. The FDA accepted the NDA filing for review in September 2017.
At September 30, 2017, the Company determined the value of the Gainesville Transaction’s contingent consideration using the following valuation approaches:
• The fair value of the regulatory milestone was estimated based on applying the likelihood of achieving the regulatory milestone and applying a discount rate from the expected time the milestone occurs to the balance sheet date. The Company expects the regulatory milestone event to occur in the third quarter of 2018 and used a discount rate of 2.8%;
• To estimate the fair value of future royalties on net sales of the Meloxicam Product, the Company assessed the likelihood of the Meloxicam Product being approved for sale and estimated the expected future sales given approval and intellectual property protection. The Company then discounted these expected payments using a discount rate of 16.0%, which the Company believes captures a market participant’s view of the risk associated with the expected payments; and
• The sales milestones were determined through the use of a real options approach, where net sales are simulated in a risk-neutral world. To employ this methodology, the Company used a risk-adjusted expected growth rate based on its assessments of expected growth in net sales of the approved Meloxicam Product, adjusted by an appropriate factor capturing their respective correlation with the market. A resulting expected (probability-weighted) milestone payment was then discounted at a rate ranging from 2.9% to 5.1%, which included cost of debt plus an alpha.
During the three and nine months ended September 30, 2017, the Company determined that the value of the Gainesville Transaction’s contingent consideration increased by $13.6 million and $15.9 million, respectively. During the three and nine months ended September 30, 2016, the value of the Gainesville Transaction’s contingent consideration decreased by $1.0 million and increased by $3.1 million, respectively. These changes were recorded as “Change in the fair value of contingent consideration” in the accompanying condensed consolidated statements of operations and comprehensive loss.
As part of the Gainesville Transaction, the Company also received warrants to purchase 350,000 shares of Recro common stock at a per share exercise price of $19.46. The Company used a Black-Scholes model with the following assumptions to determine the fair value of these warrants at September 30, 2017:
Closing stock price at September 30, 2017 |
|
$ |
8.89 |
|
Warrant strike price |
|
$ |
19.46 |
|
Expected term (years) |
|
|
4.52 |
|
Risk-free rate |
|
|
1.92 |
% |
Volatility |
|
|
80.0 |
% |
During the three and nine months ended September 30, 2017, the Company determined that the fair value of the warrants, recorded within “Other assets” in the accompanying condensed consolidated balance sheets, increased by $0.3 million and $0.1 million, respectively. The fair value of the warrants increased by $0.2 million and decreased by $0.3 million during the three and nine months ended September 30, 2016, respectively. The change in the fair value of the warrants was recorded within “Other (expense) income, net” in the accompanying condensed consolidated statements of operations and comprehensive loss.
15
ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Unaudited) (Continued)
The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term nature. The fair value of the remaining financial instruments not currently recognized at fair value on the Company’s condensed consolidated balance sheets at September 30, 2017 consisted of a $300.0 million term loan, bearing interest at LIBOR plus 2.75% with a LIBOR floor of 0.75% with a maturity date of September 25, 2021 (“Term Loan B-1”). The estimated fair value of Term Loan B-1, which was based on quoted market price indications (Level 2 in the fair value hierarchy) and which may not be representative of actual values that could have been or will be realized in the future, was as follows at September 30, 2017:
|
|
Carrying |
|
Estimated |
||
(In thousands) |
|
Value |
|
Fair Value |
||
Term Loan B-1 |
|
$ |
281,994 |
|
$ |
286,425 |
5. INVENTORY
Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Inventory consisted of the following:
|
|
September 30, |
|
December 31, |
||
(In thousands) |
|
2017 |
|
2016 |
||
Raw materials |
|
$ |
27,606 |
|
$ |
19,413 |
Work in process |
|
|
27,944 |
|
|
21,811 |
Finished goods(1) |
|
|
29,477 |
|
|
21,774 |
Total inventory |
|
$ |
85,027 |
|
$ |
62,998 |
(1) |
At September 30, 2017 and December 31, 2016, the Company had $11.9 million and $7.1 million, respectively, of finished goods inventory located at its third-party warehouse and shipping service provider. |
6. PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment consisted of the following:
|
|
September 30, |
|
December 31, |
||
(In thousands) |
|
2017 |
|
2016 |
||
Land |
|
$ |
6,293 |
|
$ |
5,913 |
Building and improvements |
|
|
155,117 |
|
|
152,871 |
Furniture, fixture and equipment |
|
|
283,731 |
|
|
251,437 |
Leasehold improvements |
|
|
19,578 |
|
|
19,241 |
Construction in progress |
|
|
38,178 |
|
|
41,254 |
Subtotal |
|
|
502,897 |
|
|
470,716 |
Less: accumulated depreciation |
|
|
(232,231) |
|
|
(205,931) |
Total property, plant and equipment, net |
|
$ |
270,666 |
|
$ |
264,785 |
16
ALKERMES PLC AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED STATEMENTS — (Unaudited) (Continued)
7. GOODWILL AND INTANGIBLE ASSETS
Goodwill and intangible assets consisted of the following:
|
|
|
|
Nine Months Ended |
|||||||
|
|
|
|
September 30, 2017 |
|||||||
(In thousands) |
|
Weighted |
|
Gross |
|
Accumulated |
|
Net Carrying |
|||
Goodwill |
|
|
|
$ |
92,873 |
|
$ |
— |
|
$ |
92,873 |
Finite-lived intangible assets: |
|
|
|
|
|
|
|
|
|
|
|
Collaboration agreements |
|
12 |
|
$ |
465,590 |
|
$ |
(256,517) |
|
$ |
209,073 |
NanoCrystal technology |
|
13 |
|
|
74,600 |
|
|
(29,544) |
|
|
45,056 |
OCR technologies |
|
12 |
|
|
42,560 |
|
|
(24,878) |
|
|
17,682 |
Total |
|
|
|
$ |
582,750 |
|
$ |
(310,939) |
|
$ |
271,811 |
Based on the Company’s most recent analysis, amortization of intangible assets included within its condensed consolidated balance sheet at September 30, 2017 is expected to be approximately $60.0 million, $60.0 million, $55.0 million, $50.0 million and $45.0 million in the years ending December 31, 2017 through 2021, respectively. Although the Company believes such available information and assumptions are reasonable, given the inherent risks and uncertainties underlying its expectations regarding such future revenues, there is the potential for the Company’s actual results to vary significantly from such expectations. If revenues are projected to change, the related amortization of the intangible assets will change in proportion to the change in revenues.
8. ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accounts payable and accrued expenses consisted of the following:
|
|
September 30, |
|
December 31, |
||
(In thousands) |
|
2017 |
|
2016 |
||
Accounts payable |
|
$ |
52,718 |
|
$ |
46,275 |
Accrued compensation |
|
|
48,229 |
|
|